Here we provide evidence that activation of the PERK branch of the UPR is involved in GBM prognoses by immunohistochemical analyses of UPR biomarkers in primary GBM specimens on a tissue microarray (TMA). This evidence concerns the gene EIF2AK3 and glioblastoma.